Last reviewed · How we verify
Havrix 720
Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in adults and children.
At a glance
| Generic name | Havrix 720 |
|---|---|
| Sponsor | Crucell Holland BV |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus antigen that triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HAV) and memory B cells, conferring long-term immunity against hepatitis A infection. The 720 designation refers to the antigen content (720 ELISA units per 0.5 mL dose).
Approved indications
- Prevention of hepatitis A infection in adults and children
Common side effects
- Injection site soreness or swelling
- Headache
- Fatigue
- Fever
- Myalgia
Key clinical trials
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (PHASE3)
- Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children (PHASE4)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (PHASE3)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs (PHASE3)
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population (PHASE3)
- Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc (PHASE4)
- Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines (PHASE3)
- A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Havrix 720 CI brief — competitive landscape report
- Havrix 720 updates RSS · CI watch RSS
- Crucell Holland BV portfolio CI